NYSE:ELAN
NYSE:ELANPharmaceuticals

Is Elanco Animal Health Still a Bargain After Its 78% Surge in 2025?

Curious if Elanco Animal Health stock is a hidden gem or already priced for perfection? You are not alone. It may be worth taking a closer look at its current valuation story. While the stock dipped 3.0% over the last week, it has surged an impressive 78.3% year-to-date and 52.7% in the past year. This suggests shifting market sentiment and renewed optimism. Much of this momentum has been driven by enthusiasm around Elanco’s strategic moves in animal healthcare innovation and recent...
NYSE:APG
NYSE:APGConstruction

APi Group (APG): Assessing Valuation After Upbeat Q3 Earnings and Raised 2025 Outlook

APi Group (APG) delivered a strong set of third quarter earnings, showing solid year-over-year growth in both sales and net income. The company also raised its revenue outlook for 2025, signaling continued momentum. See our latest analysis for APi Group. After APi Group’s upbeat third quarter report and improved 2025 outlook, investors have taken notice. The share price has surged 51.3% year-to-date, reflecting strong business momentum. The three-year total shareholder return of 186%...
NasdaqCM:LMB
NasdaqCM:LMBConstruction

Why Has Limbach Holdings (LMB) Shifted Three-Quarters of Revenue to Recurring Services?

Limbach Holdings, Inc. recently reported strong third quarter 2025 results, with sales rising to US$184.58 million and net income increasing to US$8.79 million, while also reaffirming its full-year revenue guidance. An important insight is that the company’s focus on expanding owner-direct relationships and integrating the Pioneer Power acquisition has shifted over three-quarters of its revenue to recurring service contracts, supporting operational momentum and margin growth...
NasdaqGM:ISTR
NasdaqGM:ISTRBanks

Is Investar Holding Still Trading Below Fair Value After Its Strategic Acquisition?

Ever wondered if Investar Holding is trading for less than it’s really worth? Let’s dig into what the numbers and market buzz reveal about its current value. The stock has climbed 3.4% over the past month and is up 11.9% since the start of the year, signaling renewed investor interest and possibly shifting sentiment around its growth prospects. Recently, the company completed a strategic acquisition aimed at expanding its regional presence, which has caught the eye of both analysts and...
NasdaqCM:ELDN
NasdaqCM:ELDNBiotechs

Can Eledon Pharmaceuticals’ (ELDN) Mixed Kidney Trial Results Reshape Its Competitive Edge in Transplant Care?

In November 2025, Eledon Pharmaceuticals presented results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in kidney transplant recipients at the American Society of Nephrology's Kidney Week Annual Meeting. Although the primary endpoint did not meet statistical significance, the drug showed a promising safety profile and higher kidney function in some key patient subgroups compared to standard tacrolimus therapy. We'll explore how tegoprubart's...
NasdaqGS:CLNE
NasdaqGS:CLNEOil and Gas

Clean Energy Fuels (CLNE) Is Up After Beating Q3 Estimates and Expanding RNG Supply Agreements

Earlier this month, Clean Energy Fuels Corp. reported third-quarter 2025 earnings with revenue of US$106.1 million, exceeding analyst expectations, while announcing expanded renewable natural gas (RNG) production and several new supply agreements with major fleet operators and infrastructure clients nationwide. The company also secured contracts for hydrogen fueling stations and highlighted commissioning of dairy RNG projects, pointing to diversification and growth in decarbonization...